Cancer Pain Clinical Trial
Official title:
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
Verified date | March 2024 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the long-term effectiveness of acupuncture versus massage in people living with advanced cancer. The study will test how the two approaches compare in helping people with pain and its related symptoms and improving quality of life.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | September 2024 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years or older - Having a diagnosis of the following: stage III or IV lung cancer; any stage pancreatic cancer; unresectable cholangiocarcinoma; unresectable liver cancer; unresectable ampullary or peri-ampullary cancer or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer; stage IV genitourinary cancer; stage III or IV sarcoma; stage IV melanoma; stage III or IV head/neck cancer; stage IV endocrine cancer; or hematological malignancies (lymphoma, myeloma, and leukemia) - Be ambulatory (Karnofsky functional score of = 60) - Having musculoskeletal pain, defined as regional (joints, extremities, back, neck) or more generalized (fibromyalgia or chronic widespread pain); Patients with a neuropathic component to their pain that involves the extremities or back will be eligible. - Having musculoskeletal pain for at least 1 month - Having had pain for at least 15 days in the preceding 30 days - Having a pain rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week - Having an expected prognosis of greater than six months as judged by the treating oncologist or study physician Exclusion Criteria: - Having a platelet count <15,000 - Cognitive impairment precluding response to study assessments - Unwilling to accept random assignment - Unwilling to commit to the 26-week study time period - Have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined as above. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge | New Jersey |
United States | Memorial Sloan Kettering Commack (All Protocol Activities) | Commack | New York |
United States | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison | New York |
United States | Baptist Alliance MCI | Miami | Florida |
United States | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown | New Jersey |
United States | Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale | New Jersey |
United States | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York |
United States | Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Worst Pain | Worst Pain Item from the short-form Brief Pain Inventory (BPI). The short-form BPI will be used to quantify pain severity and pain interference. The BPI contains 4 pain severity items and 7 pain interference items, all rated on a scale from 0 to 10 (higher ratings indicate worse pain intensity/interference). | 26 weeks from randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A | |
Completed |
NCT02660229 -
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
|
Phase 4 |